Rocket Retained Earnings from 2010 to 2024

RCKT Stock

USD 14.39 0.19 1.34%

Rocket Pharmaceuticals Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that Rocket Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2013-12-31

Previous Quarter

-1.1 B

Current Value

-1.2 B

Quarterly Volatility

310.9 M

Yuan Drop

Covid

Check Rocket Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rocket Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.5 M, Interest Expense of 3.3 M or Selling General Administrative of 77 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.37. Rocket financial statements analysis is a perfect complement when working with Rocket Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Rocket Pharmaceuticals Correlation against competitors.

For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.

Latest Rocket Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Rocket Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Rocket Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rocket Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (959.37 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Rocket Retained Earnings Regression Statistics

	Arithmetic Mean	(331,388,300)
	Coefficient Of Variation	(89.77)
	Mean Deviation	233,454,040
	Median	(196,023,000)
	Standard Deviation	297,494,781
	Sample Variance	88503.1T
	Range	853.5M
	R-Value	(0.84)
	Mean Square Error	28213.2T
	R-Squared	0.70
	Significance	0.000092
	Slope	(55,814,512)
	Total Sum of Squares	1239044T

Rocket Retained Earnings History

	2024	-911.4 M
	2023	-959.4 M
	2022	-713.8 M
	2021	-491.9 M
	2020	-322.8 M
	2019	-183.1 M
	2018	-105.9 M

Other Fundumenentals of Rocket Pharmaceuticals

Retained Earnings Total Equity

Rocket Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Short Long Term Debt	Short Term Investments	Capital Surpluse	Property Plant Equipment	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.24	-0.77	-0.69	0.36	0.63	0.99	0.69	0.89	0.99	0.64	0.01	0.79	0.92	0.75	-0.92	0.97	0.95	0.39	0.83
Total Stockholder Equity	0.95		-0.14	-0.7	-0.81	0.31	0.56	0.94	0.66	0.97	0.96	0.61	-0.14	0.9	0.87	0.86	-0.95	0.97	0.95	0.42	0.87
Current Deferred Revenue	-0.24	-0.14		0.23	0.05	-0.95	-0.03	-0.18	-0.13	-0.09	-0.17	-0.04	-0.17	0.03	-0.24	-0.12	0.11	-0.18	-0.11	-0.49	-0.17
Net Debt	-0.77	-0.7	0.23		0.2	-0.17	-0.33	-0.83	-0.6	-0.54	-0.79	-0.38	0.05	-0.34	-0.62	-0.36	0.6	-0.74	-0.81	0.15	-0.36
Retained Earnings	-0.69	-0.81	0.05	0.2		-0.34	-0.41	-0.62	-0.5	-0.86	-0.69	-0.45	0.2	-0.93	-0.78	-0.95	0.83	-0.75	-0.66	-0.72	-0.94
Accounts Payable	0.36	0.31	-0.95	-0.17	-0.34		0.12	0.27	0.21	0.31	0.29	0.12	0.06	0.24	0.39	0.36	-0.3	0.32	0.22	0.72	0.41
Total Liab	0.63	0.56	-0.03	-0.33	-0.41	0.12		0.63	0.49	0.53	0.58	0.65	0.49	0.58	0.52	0.39	-0.58	0.64	0.64	0.23	0.51
Total Current Assets	0.99	0.94	-0.18	-0.83	-0.62	0.27	0.63		0.67	0.87	0.99	0.67	-0.01	0.75	0.87	0.69	-0.88	0.95	0.95	0.26	0.75
Short Term Debt	0.69	0.66	-0.13	-0.6	-0.5	0.21	0.49	0.67		0.52	0.67	0.1	0.19	0.58	0.78	0.53	-0.74	0.77	0.79	0.24	0.64
Common Stock	0.89	0.97	-0.09	-0.54	-0.86	0.31	0.53	0.87	0.52		0.9	0.62	-0.21	0.95	0.81	0.89	-0.93	0.91	0.87	0.51	0.88
Net Tangible Assets	0.99	0.96	-0.17	-0.79	-0.69	0.29	0.58	0.99	0.67	0.9		0.64	-0.06	0.79	0.91	0.75	-0.92	0.96	0.95	0.34	0.81
Long Term Debt	0.64	0.61	-0.04	-0.38	-0.45	0.12	0.65	0.67	0.1	0.62	0.64		0.18	0.54	0.44	0.43	-0.51	0.55	0.54	0.17	0.43
Short Long Term Debt	0.01	-0.14	-0.17	0.05	0.2	0.06	0.49	-0.01	0.19	-0.21	-0.06	0.18		-0.13	0.07	-0.12	0.02	0.03	0.03	-0.07	-0.06
Short Term Investments	0.79	0.9	0.03	-0.34	-0.93	0.24	0.58	0.75	0.58	0.95	0.79	0.54	-0.13		0.78	0.92	-0.91	0.86	0.81	0.58	0.92
Capital Surpluse	0.92	0.87	-0.24	-0.62	-0.78	0.39	0.52	0.87	0.78	0.81	0.91	0.44	0.07	0.78		0.83	-0.91	0.91	0.86	0.53	0.91
Property Plant Equipment	0.75	0.86	-0.12	-0.36	-0.95	0.36	0.39	0.69	0.53	0.89	0.75	0.43	-0.12	0.92	0.83		-0.88	0.82	0.75	0.63	0.94
Long Term Debt Total	-0.92	-0.95	0.11	0.6	0.83	-0.3	-0.58	-0.88	-0.74	-0.93	-0.92	-0.51	0.02	-0.91	-0.91	-0.88		-0.96	-0.92	-0.5	-0.9
Net Invested Capital	0.97	0.97	-0.18	-0.74	-0.75	0.32	0.64	0.95	0.77	0.91	0.96	0.55	0.03	0.86	0.91	0.82	-0.96		0.99	0.4	0.86
Net Working Capital	0.95	0.95	-0.11	-0.81	-0.66	0.22	0.64	0.95	0.79	0.87	0.95	0.54	0.03	0.81	0.86	0.75	-0.92	0.99		0.24	0.78
Long Term Investments	0.39	0.42	-0.49	0.15	-0.72	0.72	0.23	0.26	0.24	0.51	0.34	0.17	-0.07	0.58	0.53	0.63	-0.5	0.4	0.24		0.73
Capital Stock	0.83	0.87	-0.17	-0.36	-0.94	0.41	0.51	0.75	0.64	0.88	0.81	0.43	-0.06	0.92	0.91	0.94	-0.9	0.86	0.78	0.73

Click cells to compare fundamentals

About Rocket Pharmaceuticals Financial Statements

Rocket Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Rocket Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Rocket Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Rocket Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-959.4 M	-911.4 M
Retained Earnings Total Equity	-442.7 M	-420.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC